The Journal of small animal practice · 2025
Pharmacokinetics of GS-441524 following intravenous remdesivir in six cats and results of therapeutic drug monitoring during treatment of feline infectious peritonitis: 22 cases (2021-2024).
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Coggins S J, Govendir M, Norris J M, Malik R, Hall E J, Thompson M F, Kimble B
Аннотация
OBJECTIVES: This study aimed to: (1) characterise the pharmacokinetics of GS-441524 following intravenous (iv) administration of 15 mg/kg remdesivir (RDV) in client-owned cats with feline infectious peritonitis (FIP); (2) document plasma protein binding of GS-441524 in cats; (3) determine whether trough GS-441524 plasma concentrations predict 'simple remission' or survival to 18 months; (4) measure GS-441524 concentration in effusions relative to plasma; and (5) qualitatively assess excretion of GS-441524 in urine.
MATERIALS AND METHODS: Six cats with FIP were administered 15 mg/kg iv RDV. Serial plasma GS-441524 concentrations were measured using high-performance liquid chromatography (HPLC). Twenty-two cats with FIP had trough plasma concentrations monitored over a 12-week treatment period. Simultaneous effusion and plasma GS-441524 concentrations were compared, and urine was assessed for GS-441524 excretion.
RESULTS: The mean peak plasma concentration of GS-441524 (Cmax) after a single 15 mg/kg iv dose of RDV was 2632 ng/mL (SD 862); time to reach Cmax (Tmax) was 1 hour (SD 0); and elimination half-life (t1/2) was 5.14 hours (SD 0.81). GS-441524 was present in effusions (n = 3 cats) and eliminated in urine following treatment (n = 6 cats). Assessment of the predictive relationship between median GSTC and achieving 'simple remission' failed to demonstrate a significant correlation.
CLINICAL SIGNIFICANCE: This study supports the use of RDV and GS-441524 for FIP treatment and suggests that population pharmacokinetic modelling is required to better explore the utility of therapeutic drug monitoring of GS-441524.
MATERIALS AND METHODS: Six cats with FIP were administered 15 mg/kg iv RDV. Serial plasma GS-441524 concentrations were measured using high-performance liquid chromatography (HPLC). Twenty-two cats with FIP had trough plasma concentrations monitored over a 12-week treatment period. Simultaneous effusion and plasma GS-441524 concentrations were compared, and urine was assessed for GS-441524 excretion.
RESULTS: The mean peak plasma concentration of GS-441524 (Cmax) after a single 15 mg/kg iv dose of RDV was 2632 ng/mL (SD 862); time to reach Cmax (Tmax) was 1 hour (SD 0); and elimination half-life (t1/2) was 5.14 hours (SD 0.81). GS-441524 was present in effusions (n = 3 cats) and eliminated in urine following treatment (n = 6 cats). Assessment of the predictive relationship between median GSTC and achieving 'simple remission' failed to demonstrate a significant correlation.
CLINICAL SIGNIFICANCE: This study supports the use of RDV and GS-441524 for FIP treatment and suggests that population pharmacokinetic modelling is required to better explore the utility of therapeutic drug monitoring of GS-441524.